Ureaplasma, bronchopulmonary dysplasia, and azithromycin in European neonatal intensive care units: a survey

Pansieri, Claudia, Pandolfini, Chiara, Elie, Valery, Turner, Mark A., Kotecha, Sailesh ORCID: https://orcid.org/0000-0003-3535-7627, Jacqz-Aigrain, Evelyne and Bonati, Maurizio 2014. Ureaplasma, bronchopulmonary dysplasia, and azithromycin in European neonatal intensive care units: a survey. Scientific Reports 4 , 4076. 10.1038/srep04076

Full text not available from this repository.

Abstract

A survey was set up to gauge the opinions of neonatologists on the role of Ureaplasma in bronchopulmonary dysplasia (BPD) development, the use of azithromycin for BPD prevention, and the factors influencing azithromycin use in European neonatal intensive care units (NICUs). 167 NICUs participated in the survey, representing 28 European countries. For respondents, the two major perceived risk factors for BPD were prematurity of <28 weeks and high oxygen requirements. Only 38% of NICUs had a protocol for BPD prevention and 47% routinely tested for Ureaplasma. In cases of infection, macrolides were the first choice. Most (78%) NICUs were interested in participating in a trial evaluating azithromycin safety and efficacy in reducing BPD rates. Opinions and clinical practice varied between European neonatal units, and differences in Ureaplasma treatment and prevention of BPD highlight the need for further azithromycin evaluation and for improved therapeutic knowledge in preterms.

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General)
Publisher:	Nature Publishing Group
ISSN:	2045-2322
Date of Acceptance:	27 January 2014
Last Modified:	31 Oct 2022 09:02
URI:	https://orca.cardiff.ac.uk/id/eprint/79610

Citation Data

Cited 5 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item